Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q Fever LPS Conjugate Vaccine
- Development stage
- Preclinical
- Lead developer
- Hilleman Laboratories
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
The Q Fever LPS Conjugate Vaccine is a preclinical vaccine candidate being developed by Hilleman Laboratories for the prevention of Q Fever, a zoonotic infection caused by the bacterium *Coxiella burnetii*. The vaccine utilizes a conjugate platform where the lipopolysaccharide (LPS) of *C. burnetii* is chemically linked to a carrier protein. This design aims to overcome the limitations of traditional whole-cell vaccines, which can cause severe hypersensitivity reactions in individuals previously exposed to the pathogen. By conjugating the LPS antigen, the vaccine is intended to convert the T-cell independent carbohydrate antigen into a T-cell dependent one, thereby inducing a more robust and long-lasting immune response with an improved safety profile.
- Other names
- Coxiella burnetii LPS-conjugate vaccineQ fever lipopolysaccharide conjugate vaccine
02
Targets
Coxiella burnetii phase I lipopolysaccharide O-antigen epitope
Beyond the preview
Go deeper on Q Fever LPS Conjugate Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q Fever LPS Conjugate Vaccine.